Downgrade to Reduce on valuation concerns **Premium valuations unjustified; prefer Nestle for a more diverse portfolio mix**

Action: Downgrade to Reduce; stable business, but valuations not justified given the completion of the open offer

GlaxoSmithKline PLC (GSK LN, Neutral) has now completed an open offer to acquire an additional stake in its Indian subsidiary. Post the completion of the open offer, the parent company's stake has increased from 43.16% to 72.46%. The open offer was made at INR3,900 per share which closed on 30 January 2013. We believe GSK Consumer (SKB) will still deliver ~20% profit growth in the next couple of years. However, at 30.7x CY13F EPS, GSK trades at a significant premium to its three-year average of 25x. We prefer Nestle (NEST IN, Neutral) on a relative basis at similar multiples which has a more diverse portfolio mix. Within the food subsector, we prefer Jubilant Foodworks (JUBI IN, Buy) as its long-term potential to drive earnings growth is significantly higher, in our view.

Catalysts: Valuations should correct to reflect a stable earnings growth period and bid premium should disappear

The catalyst for the shares to drift lower will be on account of SKB's valuations reducing to reflect the long-term earnings growth trajectory. **Valuation: GSK Consumer trades at 25.4x**

SKB trades at 25.4x CY14F EPS vs. the sector average of ~23.9x FY15F. We believe the valuation has run ahead of the earnings growth potential due to the possibility of a delisting at some point in the future. While we believe GSK Consumer will still deliver ~20% earnings growth over the next couple of years, we prefer Jubilant Foodworks at current valuations (25.8x FY15F) for which the earnings growth over the next couple of years should be significantly higher at ~37%. We also have a relative preference for Nestlé which has a much more diverse portfolio mix and hence a lower risk profile.

31 Dec	FY11		FY12F		FY13F		FY14F
Currency (INR)	Actual	Old	New	Old	New	Old	New
Revenue (mn)	26,855	31,413	31,413	37,071	37,071	44,208	44,208
Reported net profit (mn)	3,552	4,267	4,267	5,129	5,129	6,198	6,198
Normalised net profit (mn)	3,443	4,267	4,267	5,129	5,129	6,198	6,198
FD normalised EPS	81.86	101.46	101.46	121.95	121.95	147.37	147.38
FD norm. EPS growth (%)	19.0	23.9	24.0	20.2	20.2	20.8	20.9
FD normalised P/E (x)	45.7	N/A	36.9	N/A	30.7	N/A	25.4
EV/EBITDA (x)	28.8	N/A	23.7	N/A	19.2	N/A	15.7
Price/book (x)	13.8	N/A	11.6	N/A	9.7	N/A	8.1
Dividend yield (%)	1.1	N/A	1.2	N/A	1.6	N/A	1.9
ROE (%)	33.8	34.1	34.1	34.4	34.4	34.7	34.7
Net debt/equity (%)	net cash						
Net debt/equity (%)	net cash						

Source: Company data, Nomura estimates

Key company data: See page 2 for company data and detailed price/index chart.

February 19, 2013	
Rating Down from Buy	Reduce
Target price Increased from 3100	INR 3400
Closing price February 18, 2013	INR 3779
Potential downside	-10%

Anchor themes

GSK Consumer is the leader in the malted beverages market in India, with a 70% share. With low category penetration levels and the spend on packaged foods increasing, GSK Consumer is an attractive opportunity in the long term.

Nomura vs consensus

Consensus TPs are disconnected from the earnings growth because of the open offer but our earnings estimates are in line with consensus for the next couple of years.

Research analysts

India Consumer Related

Manish Jain - NFASL manish.jain@nomura.com +91 22 4037 4186

Anup Sudhendranath - NSFSPL anup.sudhendranath@nomura.com +91 22 4037 5406

See Appendix A-1 for analyst certification, important disclosures and the status of non-US analysts.

Key data on GSK Consumer Healthcare

Income statement (INRmn)

Income statement (INRmn)					
Year-end 31 Dec	FY10	FY11	FY12F	FY13F	FY14F
Revenue	23,061	26,855	31,413	37,071	44,208
Cost of goods sold	-11,053	-12,990	-15,591	-18,337	-21,777
Gross profit	12,008	13,865	15,822	18,733	22,431
SG&A	-5,709	-6,658	-7,283	-8,644	-10,489
Employee share expense	-2,297	-2,584	-3,046	-3,473	-3,955
Operating profit	4,003	4,623	5,494	6,617	7,987
EBITDA	4,400	5,083	6,023	7,290	8,750
Depreciation	-397	-460	-529	-674	-764
Amortisation	0	0	0	0	0
EBIT	4,003	4,623	5,494	6,617	7,987
Net interest expense	-26	-35	-36	-44	-40
Associates & JCEs	0	0	0	0	0
Other income	435	704	930	1,105	1,332
Earnings before tax	4,412	5,293	6,388	7,678	9,279
Income tax	-1,520	-1,851	-2,121	-2,549	-3,081
Net profit after tax	2,892	3,443	4,267	5,129	6,198
Minority interests	0	0	0	0	0
Other items	0	0	0	0	0
Preferred dividends	0	0	0	0	0
Normalised NPAT	2,892	3,443	4,267	5,129	6,198
Extraordinary items	107	110	0	0	0
Reported NPAT	2,999	3,552	4,267	5,129	6,198
Dividends	-2,452	-1,711	-1,892	-2,523	-2,944
Transfer to reserves	547	1,841	2,375	2,605	3,254
		· · · ·		· · · ·	
Valuation and ratio analysis					
Reported P/E (x)	52.5	44.3	36.9	30.7	25.4
Normalised P/E (x)	54.4	45.7	36.9	30.7	25.4
FD normalised P/E (x)	54.4	45.7	36.9	30.7	25.4
FD normalised P/E at price target (x)	49.4	41.5	33.5	27.9	23.1
Dividend yield (%)	1.6	1.1	1.2	1.6	1.9
Price/cashflow (x)	30.7	42.0	23.7	21.8	22.9
Price/book (x)	16.4	13.8	11.6	9.7	8.1
EV/EBITDA (x)	33.6	28.8	23.7	19.2	15.7
EV/EBIT (x)	36.9	31.7	26.0	21.1	17.2
Gross margin (%)	52.1	51.6	50.4	50.5	50.7
EBITDA margin (%)	19.1	18.9	19.2	19.7	19.8
EBIT margin (%)	17.4	17.2	17.5	17.8	18.1
Net margin (%)	13.0	13.2	13.6	13.8	14.0
Effective tax rate (%)	34.4	35.0	33.2	33.2	33.2
Dividend payout (%)	81.8	48.2	44.4	49.2	47.5
Capex to sales (%)	4.8	3.7	2.8	5.0	2.8
Capex to depreciation (x)	2.8	2.2	1.7	2.7	1.6
ROE (%)	32.2	33.8	34.1	34.4	34.7
ROA (pretax %)	58.0	51.8	52.5	54.0	54.4
Growth (%)	00.0	40 5	47.0	40.0	40.0
	20.0	16.5	17.0	18.0	19.3
	20.6	15.5	18.5	21.0	20.0
EBIT	24.0	15.5	18.8	20.4	20.7
Normalised EPS Normalised FDEPS	<u> </u>	<u> </u>	24.0 24.0	20.2	20.9 20.9
Per share	=	0.1.10	404.40	40/ 07	4
Reported EPS (INR)	71.30	84.46	101.46	121.95	147.38
Norm EPS (INR)	68.77	81.86	101.46	121.95	147.38
Fully diluted norm EPS (INR)	68.77	81.86	101.46	121.95	147.38
Book value per share (INR)	228.28	272.06	323.61	385.56	462.94
DPS (INR)	58.30	40.68	45.00	60.00	70.00

Source: Company data, Nomura estimates

Relative performance chart (one year)



Source: ThomsonReuters, Nomura research

(%)	1M	ЗM	12M	
Absolute (INR)	-2.4	24.7	41.7	
Absolute (USD)	-1.7	26.4	29.2	
Relative to index	0.6	20.0	35.5	
Market cap (USDmn)	2,911.2			
Estimated free float (%)	27.5			
52-week range (INR)	4391/2400			
3-mth avg daily turnover (USDmn)	3.49			
Major shareholders (%)				
Horlicks Ltd	72.5			
LIC India	5.9			
Source: Thomson Reuters,	Nomura research	n		

Notes

Cashflow (INRmn)

Year-end 31 Dec	FY10	FY11	FY12F	FY13F	FY14F
EBITDA	4,400	5,083	6,023	7,290	8,750
Change in working capital	1,797	-194	1,871	1,429	-86
Other operating cashflow	-1,071	-1,138	-1,266	-1,488	-1,789
Cashflow from operations	5,125	3,751	6,628	7,231	6,876
Capital expenditure	-1,110	-1,004	-889	-1,850	-1,250
Free cashflow	4,015	2,746	5,738	5,381	5,626
Reduction in investments	0	0	0	0	0
Net acquisitions					
Reduction in other LT assets	0	0	0	0	0
Addition in other LT liabilities	0	0	0	0	0
Adjustments					
Cashflow after investing acts	4,015	2,746	5,738	5,381	5,626
Cash dividends	-2,452	-1,711	-1,892	-2,523	-2,944
Equity issue	0	0	0		
Debt issue	0	0	0		
Convertible debt issue					
Others					
Cashflow from financial acts	-2,452	-1,711	-1,892	-2,523	-2,944
Net cashflow	1,563	1,036	3,846	2,858	2,682
Beginning cash	8,198	9,761	10,797	14,642	17,500
Ending cash	9,761	10,797	14,642	17,500	20,182
Ending net debt	-9,761	-10,797	-14.642	-17,500	-20,182

Balance sheet (INRmn)

As at 31 Dec	FY10	FY11	FY12F	FY13F	FY14F
Cash & equivalents	9,761	10,797	14,642	17,500	20,182
Marketable securities	0	0	0	0	0
Accounts receivable	505	992	1,126	1,320	1,575
Inventories	3,120	3,700	3,696	5,067	6,063
Other current assets	1,112	1,612	2,169	2,140	2,544
Fotal current assets	14,499	17,100	21,634	26,027	30,364
LT investments	0	0	0	0	0
Fixed assets	3,106	3,718	3,911	5,087	5,573
Goodwill	0	0	0	0	0
Other intangible assets	0	0	0	0	0
Other LT assets	0	0	0	0	0
Fotal assets	17,604	20,817	25,545	31,114	35,937
Short-term debt	0	0	0	0	0
Accounts payable	4,704	6,663	8,414	9,141	10,901
Other current liabilities	3,300	2,712	3,521	5,758	5,567
Total current liabilities	8,004	9,376	11,935	14,899	16,468
_ong-term debt	0	0	0	, 0	0
Convertible debt	0	0	0	0	0
Other LT liabilities	0	0	0	0	0
Fotal liabilities	8,004	9,376	11,935	14,899	16,468
Minority interest	0	0	0	0	0
Preferred stock	0	0	0	0	0
Common stock	421	421	421	421	421
Retained earnings	9,180	11,021	13,189	15,794	19,049
Proposed dividends					
Other equity and reserves					
Total shareholders' equity	9,600	11,442	13,610	16,215	19,469
Fotal equity & liabilities	17,604	20,817	25,545	31,114	35,937
Liquidity (x)					
Current ratio	1.81	1.82	1.81	1.75	1.84
Interest cover	153.9	133.4	152.6	150.4	199.7
	10010		.02.0		
Leverage					
Net debt/EBITDA (x)	net cash				
Net debt/equity (%)	net cash				
Activity (days)					
Days receivable	6.5	10.2	12.3	12.0	12.0
Days inventory	95.4	95.8	86.8	87.2	93.3
Days payable	139.6	159.7	177.0	174.7	168.0
Cash cycle	-37.7	-53.7	-77.8	-75.5	-62.7
Source: Company data, Nomura estimates					

Source: Company data, Nomura estimates

3M performance driven by the open offer announcement

The stock performance over the past three months has been driven by the announcement of an open offer from the parent company GlaxoSmithKline PLC (GSK LN) for its listed subsidiary. The open offer was announced with the intention of taking its share holding up from 43.16% to 75%. The total offer was to acquire 13.39mn shares, of which there was an acceptance ratio of 92%, or 12.32mn shares which were tendered. Post the offer, the stake of the parent company has increased to 72.46%.

Charle	Tielss	44 Eab 40	00 Nov 40	
Stock	Ticker	14-Feb-13	23-Nov-12	3M Return
GSK Consumer	SKB IN	3,836	3,049	26%
Asian Paints	APNT IN	4,526	4,054	12%
Dabur	DABUR IN	134	122	9%
Sensex	SENSEX	19,497	18,507	5%
ITC	ITC IN	301	287	5%
Emami	HMN IN	619	593	4%
Godrej Consumer	GCPL IN	711	688	3%
United Spirits	UNSP IN	1,894	1,880	1%
FMCG Index	BSETMCG	5,802	5,815	0%
Nestle India	NEST IN	4,598	4,620	0%
Colgate Palmolive	CLGT IN	1,312	1,327	-1%
Marico	MRCO IN	211	214	-1%
Titan Industries	TTAN IN	269	296	-9%
Jubilant Foodworks	JUBI IN	1,108	1,258	-12%
Hindustan Unilever	HUVR IN	465	530	-12%

Source: Bloomberg, Nomura research

Parent's stake now the highest among MNC consumer companies

Post the open offer, GlaxoSmithKline's parent now has the highest stake in its Indian subsidiary across the names in the sector. Unilever has a 52.5% stake in HUVR, Nestle has 62.8% stake in Nestle India and Colgate has a 51% stake in Colgate Palmolive India. There remains a possibility that over the next few years, parent companies might look to increase their stakes in these companies, in our view. However, given the regulation that all listed companies should have a minimum 75% shareholding with the non-promoter group, an increase in stakes is more likely for other companies than SKB from current levels, in our view.

oanies in Indian subsid	iaries
Ticker	Parent's stake in Indian subsidiary
SKB IN	72.5%
HUVR IN	52.5%
NEST IN	62.8%
CLGT IN	51.0%
	Ticker SKB IN HUVR IN NEST IN

Source: Bombay Stock Exchange

Surprisingly, the share price has not corrected post the closing of the open offer

The open offer closed on January 30, 2013, with the payment being disbursed to the shareholders who tendered their shares by February 13, 2013. We expected the stock to correct back to its normalised P/E band once the open offer was closed, but surprisingly the stock held firm. We see two reasons for this:


- -First, given the large number of shareholders who have already tendered their shares, the free float has reduced considerably.
- -Secondly, shareholders who did not tender their shares in the open offer are now holding out for a larger premium to the current share price and a possible delisting of shares in the next few years.

We believe these reasons will continue to support SKB's share price in the near term, but over the next three months or so, we see valuations returning to more normalised levels.

GSK's earnings growth trajectory similar to Nestle

If we look at both the past and present earnings growth trajectories for Nestle and SKB, the difference in growth rates was minimal. However, over the next couple of years we expect Nestle to grow at a marginally higher rate than SKB.


Fig. 3: Earnings growth similar to Nestle




Source: Company, Nomura estimates

However, Nestle has a much wider and diverse product portfolio

However, importantly Nestle has a much wider portfolio of products, which means risks to earnings growth are much lower, in our view. Nestlé's portfolio mix consists of ~49% from milk and milk products, ~28% from prepared dishes and cooking aids, ~13.5% from chocolates and ~9.5% from beverages. This compares unfavourable with SKB for which >90% of sales comes from the milk food category which has not seen any significant change over the past few years, we believe.







Source: Company, Nomura research


Source: Company, Nomura research

SKB will continue to have a consistent profit growth delivery

We expect SKB to continue to deliver ~20% earnings growth over the next couple of years (CY13-14F). This will be driven by consistent topline delivery with volume growth continuing to be in the 9-10% range and a price/mix of ~8%. We are not building in any significant gain on the gross margins front for CY13F, but believe operating leverage can help the company deliver some level of operating margin improvement.

However, there remains no significant upside potential for surprises, given the nature of the portfolio, in our view. We expect the company to retain market share in the category and its growth to be in line with the category growth rate. As discussed earlier, the reliance on one segment makes SKB's earnings more volatile, in our view, than Nestlé.






Source: Company data, Nomura estimates

How does current valuations compare with the long-term history?

Current valuations are at a significant premium to both the near-term history as well as the long-term average. The stock's five-year average P/E is 21x one-year forward and even the past three-year average is close to 25x, which includes a period of high P/E since the open offer was made. This compares with the current one-year forward P/E of 30.7x, a significant premium to both long-term and three-year averages for the stock, in our view.






Source: Bloomberg, Nomura research

How does current valuations compare with Nestle?

SKB is also at a premium to Nestle, although the diversification of the product portfolio is much inferior. Nestlé also offers a marginally higher growth rate potential over the next couple of years vs. SKB, in our view. The long-term average discount for SKB vs. Nestle is 33% vs. a 4% premium currently. This, we believe, is unjustified as we also have a Neutral rating on Nestlé on account of its high valuations.

Even if we compare with Jubilant Foodworks, for which the earnings growth over the next couple of years (average 37%) should be almost 2x, on our numbers, the expected growth rate (our expectation) at SKB is expensive, we believe.

Fig. 8: GSK Consumer vs. Nestle India one-year forward P/E



Source: Bloomberg, Nomura research

What are the risks to our call?

We see two risks to our call.

-First, shareholders who have not tendered in the open offer remain on board and wait for a delisting premium to be offered to them in the future. This will ensure that trading volumes in the stock suffer and a liquidity premium is built into the stock. We

acknowledge that this is possible, but the earnings growth trajectory does not justify the current valuations, in our view.

-Second, there are significant surprises on margin performance over the next couple of years, driven by higher pricing. However, we see this risk as minimal, given the competitive nature of the main category in which the company operates as well as the demand elasticity to pricing.

Downgrading to Reduce; TP raised as a result of the roll forward of valuations

We downgrade our rating to Reduce from Buy as the earnings growth trajectory does not justify current valuations. We see better opportunity in owning Nestle India and Jubilant Foodworks at current levels. A potential upside surprise is more likely at Jubilant Foodworks, where the earnings growth can surprise over the next couple of years. We raise our TP from INR3,100 to INR3,400. The increase in TP is on account of two factors:

- -First, the roll forward of valuations by one quarter. Our valuation multiple remains unchanged at 25x. We believe this reflects both the past three years' trading band for the company as well as the ~20% earnings growth we expect the company to deliver over the next couple of years.
- -Secondly to reflect the higher level of cash on the balance sheet, which has moved up from INR10.79bn in CY11 to INR14.64bn as in end-CY12. This means that cash per share has moved up from INR257 per share to INR 348 per share.

We use a sum-of-the-parts methodology (unchanged) to value SKB. We value the core operating business at 25x one-year forward EPS of INR122, which gives a value of INR3,052. We value cash at book value. As at the end of CY12, the company had cash of INR14.6bn, which works out to INR348 per share. Adding together the core business value and cash on the balance sheet gives us a combined value of INR3,400.

Company	Ticker	Rating	Price INR	EPS growth FY14E %	EPS growth FY15E %	FY14E P/E	FY15E P/E	FY14E PEG	FY15E PEG	Market cap USD mn
Nestle *	NEST IN	Neutral	4,597	22%	23%	30.1x	24.5x	1.4x	1.1x	8,059
GSK Consumer *	SKB IN	Reduce	3,742	20%	21%	30.7x	25.4x	1.5x	1.2x	2,865
Jubilant Foodworks	JUBI IN	Buy	1,112	39%	34%	34.6x	25.8x	0.9x	0.8x	1,305
United Spirits	UNSP IN	Buy	1,898	139%	49%	39.4x	26.4x	0.3x	0.5x	4,513
F&B Average						33.1x	25.3x			
Colgate Palmolive	CLGT IN	Reduce	1,317	14%	15%	30.7x	26.8x	2.2x	1.9x	3,256
Dabur	DABUR IN	Buy	133	20%	18%	25.0x	21.2x	1.2x	1.2x	4,214
Godrej Consumer	GCPL IN	Buy	725	24%	24%	25.6x	20.7x	1.1x	0.9x	4,487
Hindustan Unilever	HUVR IN	Reduce	462	14%	11%	28.8x	25.9x	2.1x	2.3x	18,165
Marico	MRCO IN	Neutral	213	21%	22%	25.9x	21.3x	1.2x	1.0x	2,381
Emami	HMN IN	Buy	622	18%	18%	25.1x	21.3x	1.4x	1.2x	1,712
HPC Average						27.7x	24.2x			
ITC	ITC IN	Buy	301	18%	19%	27.5x	23.0x	1.6x	1.2x	42,731
Asian Paints	APNT IN	Neutral	4,542	20%	20%	31.8x	26.5x	1.6x	1.3x	7,922
Titan Industries	TTAN IN	Buy	268	21%	24%	25.5x	20.7x	1.2x	0.9x	4,323

Fig. 9: Consumer sector valuation

Source: Bloomberg, Nomura estimates. Prices as on February 15, 2013. *Denotes calendar year valuations

Appendix A-1

Analyst Certification

We, Manish Jain and Anup Sudhendranath, hereby certify (1) that the views expressed in this Research report accurately reflect our personal views about any or all of the subject securities or issuers referred to in this Research report, (2) no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this Research report and (3) no part of our compensation is tied to any specific investment banking transactions performed by Nomura Securities International, Inc., Nomura International plc or any other Nomura Group company.

Issuer Specific Regulatory Disclosures


The term "Nomura Group" used herein refers to Nomura Holdings, Inc. or any of its affiliates or subsidiaries, and may refer to one or more Nomura Group companies.

Materially mentioned issuers

Issuer	Ticker	Price	Price date	Stock rating	Sector rating	Disclosures
GlaxoSmithKline	GSK LN	1471p	15-Feb-2013	Neutral	Bearish	A4,A6
Jubilant Foodworks	JUBI IN	INR 1109	18-Feb-2013	Buy	Not rated	
Nestle India	NEST IN	INR 4567	18-Feb-2013	Neutral	Not rated	
GSK Consumer						
Healthcare	SKB IN	INR 3779	18-Feb-2013	Reduce	Not rated	

A4 The Nomura Group had an investment banking services client relationship with the issuer during the past 12 months.

A6 The Nomura Group expects to receive or intends to seek compensation for investment banking services from the issuer in the next three months.




Valuation Methodology We have used a sum-of-the-parts methodology to value GSK Consumer. We value the core operating business at 25x one-year forward EPS of INR122, which gives a value of INR3,052. We value cash at book value. As at the end of CY12, the company had cash of INR14.6bn, which works out to INR348 per share. Adding together the core business value and cash on the balance sheet gives us a combined value of INR3,400.

Risks that may impede the achievement of the target price A sharp rise in commodity costs and marketing spending is the key downside risk to our estimates.



GlaxoSmithKline (GSK LN)


1471p (15-Feb-2013) Neutral (Sector rating: Bearish)



For explanation of ratings refer to the stock rating keys located after $\mbox{chart}(s)$

Valuation Methodology We believe that the stock should trade in line to the sector's 2013E P/E multiple, as the company offers a 2012-16E EPS CAGR of 6.8% versus the consensus expectation for the sector at 5.8%. Therefore, we apply no discount to our 2013E EPS of 118p. Our DCF methodology using three-stage cash flows projects to 2020, discounted to today (WACC 8.8%; terminal growth 0%). Modulating our P/E and DCF valuation with our PharmaForecasts equity NPV valuation provides a target price of GBP 13.40. The relative index for these stocks is Dow Jones Euro STOXX® TM Pharmaceuticals.

Risks that may impede the achievement of the target price In addition to the typical pharmaceutical industry risks associated with potential product approval delays and withdrawals, we believe that GSK has significant risk associated with currency movements; fluctuations in sterling relative to other major currencies (US dollar, euro) would affect our EPS estimates. Pricing pressure in the United States that restricts the company's ability effectively to manage Advair pricing would affect our estimates. Large to midsize acquisitions would affect our estimates.




Valuation Methodology We use a DCF-based valuation approach to arrive at our target price of INR1,330. Key underlying assumptions are 24.5% medium-term growth followed by 18% long-term growth and 6% terminal growth. Our cost of equity assumption is 12% and we discount back cashflows to FY13F.

Risks that may impede the achievement of the target price Higher-than-expected raw material prices and slowing samestore sales growth are key risks.

INR 4567 (18-Feb-2013) Neutral (Sector rating: Not rated)

Nestle India (NEST IN)



Valuation Methodology Our target price of INR4,516 is based on P/E multiple of 28x on our four forward quarters earnings estimates.

Risks that may impede the achievement of the target price Negative risks arise from further increases in input prices and higher A&P spending. Positive risks come from better price/mix improvement vs our expectations.

Important Disclosures

Online availability of research and conflict-of-interest disclosures

Nomura research is available on <u>www.nomuranow.com/research</u>, Bloomberg, Capital IQ, Factset, MarkitHub, Reuters and ThomsonOne. Important disclosures may be read at <u>http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx</u> or requested from Nomura Securities International, Inc., on 1-877-865-5752. If you have any difficulties with the website, please email <u>grpsupport-</u> <u>eu@nomura.com</u> for help.

The analysts responsible for preparing this report have received compensation based upon various factors including the firm's total revenues, a portion of which is generated by Investment Banking activities. Unless otherwise noted, the non-US analysts listed at the front of this report are not registered/qualified as research analysts under FINRA/NYSE rules, may not be associated persons of NSI, and may not be subject to FINRA Rule 2711 and NYSE Rule 472 restrictions on communications with covered companies, public appearances, and trading securities held by a research analyst account.

Nomura Global Financial Products Inc. ("NGFP") Nomura Derivative Products Inc. ("NDPI") and Nomura International plc. ("NIplc") are registered with the Commodities Futures Trading Commission and the National Futures Association (NFA) as swap dealers. NGFP, NDPI, and NIplc are generally engaged in the trading of swaps and other derivative products, any of which may be the subject of this report.

Any authors named in this report are research analysts unless otherwise indicated. *Industry Specialists* identified in some Nomura International plc research reports are employees within the Firm who are responsible for the sales and trading effort in the sector for which they have coverage. Industry Specialists do not contribute in any manner to the content of research reports in which their names appear. *Marketing Analysts* identified in some Nomura research reports are research analysts employed by Nomura International plc who are primarily responsible for marketing Nomura's Equity Research product in the sector for which they have coverage. Marketing Analysts may also contribute to research reports in which their names appear and publish research on their sector.

Distribution of ratings (Global)

The distribution of all ratings published by Nomura Global Equity Research is as follows:

43% have been assigned a Buy rating which, for purposes of mandatory disclosures, are classified as a Buy rating; 41% of companies with this rating are investment banking clients of the Nomura Group*.

45% have been assigned a Neutral rating which, for purposes of mandatory disclosures, is classified as a Hold rating; 46% of companies with this rating are investment banking clients of the Nomura Group*.

12% have been assigned a Reduce rating which, for purposes of mandatory disclosures, are classified as a Sell rating; 26% of companies with this rating are investment banking clients of the Nomura Group*.

As at 31 December 2012. *The Nomura Group as defined in the Disclaimer section at the end of this report.

Explanation of Nomura's equity research rating system in Europe, Middle East and Africa, US and Latin America The rating system is a relative system indicating expected performance against a specific benchmark identified for each individual stock. Analysts may also indicate absolute upside to target price defined as (fair value - current price)/current price, subject to limited management discretion. In most cases, the fair value will equal the analyst's assessment of the current intrinsic fair value of the stock using an appropriate valuation methodology such as discounted cash flow or multiple analysis, etc.

STOCKS

A rating of 'Buy', indicates that the analyst expects the stock to outperform the Benchmark over the next 12 months. A rating of 'Reduce', indicates that the analyst expects the stock to perform in line with the Benchmark over the next 12 months. A rating of 'Reduce', indicates that the analyst expects the stock to underperform the Benchmark over the next 12 months. A rating of 'Suspended', indicates that the rating, target price and estimates have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including, but not limited to, when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the company. Benchmarks are as follows: United States/Europe: please see valuation methodologies for explanations of relevant benchmarks for stocks, which can be accessed at: http://go.nomuranow.com/research/globalresearchportal/pages/disclosures/disclosures.aspx; Global Emerging Markets (ex-Asia): MSCI Emerging Markets ex-Asia, unless otherwise stated in the valuation methodology.

SECTORS

A 'Bullish' stance, indicates that the analyst expects the sector to outperform the Benchmark during the next 12 months. A 'Neutral' stance, indicates that the analyst expects the sector to perform in line with the Benchmark during the next 12 months. A 'Bearish' stance, indicates that the analyst expects the sector to underperform the Benchmark during the next 12 months. Benchmarks are as follows: United States: S&P 500; Europe: Dow Jones STOXX 600; Global Emerging Markets (ex-Asia): MSCI Emerging Markets ex-Asia.

Explanation of Nomura's equity research rating system in Japan and Asia ex-Japan stocks

STOCKS

Stock recommendations are based on absolute valuation upside (downside), which is defined as (Target Price - Current Price) / Current Price, subject to limited management discretion. In most cases, the Target Price will equal the analyst's 12-month intrinsic valuation of the stock, based on an appropriate valuation methodology such as discounted cash flow, multiple analysis, etc. A '**Buy'** recommendation indicates that potential upside is 15% or more. A '**Neutral'** recommendation indicates that potential upside is less than 15% or downside is less than 5%. A '**Reduce'** recommendation indicates that potential downside is 5% or more. A rating of '**Suspended'** indicates that the rating and target price have been suspended temporarily to comply with applicable regulations and/or firm policies in certain circumstances including when Nomura is acting in an advisory capacity in a merger or strategic transaction involving the subject company. Securities and/or companies that are labelled as '**Not rated'** or shown as '**No rating'** are not in regular research coverage of the Nomura entity identified in the top banner. Investors should not expect continuing or additional information from Nomura relating to such securities and/or companies.

SECTORS

A '**Bullish'** rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a positive absolute recommendation. A '**Neutral'** rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a neutral absolute recommendation. A '**Bearish'** rating means most stocks in the sector have (or the weighted average recommendation of the stocks under coverage is) a negative absolute recommendation.

Target Price A Target Price, if discussed, reflects in part the analyst's estimates for the company's earnings. The achievement of any target price may be impeded by general market and macroeconomic trends, and by other risks related to the company or the market, and may not occur if the company's earnings differ from estimates.

Disclaimers

This document contains material that has been prepared by the Nomura entity identified at the top or bottom of page 1 herein, if any, and/or, with the sole or joint contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the contributions of one or more Nomura entities whose employees and their respective affiliations are specified on page 1 herein or identified elsewhere in the document. The term "Nomura Group" used herein refers to Nomura Holdings, Inc. or any of its affiliates or subsidiaries and may refer to one or more Nomura Group companies including: Nomura Securities Co., Ltd. ('NSC') Tokyo, Japan; Nomura International plc ('NIplc'), UK; Nomura Securities International, Inc. ('NSI'), New York, US; Nomura International (Hong Kong) Ltd. ('NIHK'), Hong Kong; Nomura Financial Investment (Korea) Co., Ltd. ('NFIK'), Korea (Information on Nomura analysts registered with the Korea Financial Investment Association ('KOFIA') can be found on the KOFIA Intranet at http://dis.kofia.or.kr; Nomura Singapore Ltd. ('NSL'), Singapore (Registration number 197201440E, regulated by the Monetary Authority of Singapore); Nomura Australia Ltd. ('NAL'), Australia (ABN 48 003 032 513), regulated by the Australian Securities and Investment Commission ('ASIC') and holder of an Australian financial services licence number 246412; P.T. Nomura Indonesia ('PTNI'), Indonesia; Nomura Securities Malaysia Sdn. Bhd. ('NSM'), Malaysia; NIHK, Taipei Branch ('NITB'), Taiwan; Nomura Financial Advisory and Securities (India) Private Limited ('NFASL'), Mumbai, India (Registered Address: Ceejay House, Level 11, Plot F, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai- 400 018, India; Tel: +91 22 4037 4037, Fax: +91 22 4037 4111; SEBI Registration No: BSE INB011299030, NSE INB231299034, INF231299034, INE 231299034, MCX: INE261299034); NIplc, Madrid Branch ('NIplc, Madrid') and NIplc, Italian Branch ('NIplc, Italy'). 'CNS Thailand' next to an analyst's name on the front page of a research report indicates that the analyst is employed by Capital Nomura Securities Public Company Limited ('CNS') to provide research assistance

services to NSL under a Research Assistance Agreement. CNS is not a Nomura entity. THIS MATERIAL IS: (I) FOR YOUR PRIVATE INFORMATION, AND WE ARE NOT SOLICITING ANY ACTION BASED UPON IT; (II) NOT TO BE CONSTRUED AS AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITY IN ANY JURISDICTION WHERE SUCH OFFER OR SOLICITATION WOULD BE ILLEGAL; AND (III) BASED UPON INFORMATION FROM SOURCES THAT WE CONSIDER RELIABLE, BUT HAS NOT BEEN INDEPENDENTLY VERIFIED BY NOMURA GROUP

Nomura Group does not warrant or represent that the document is accurate, complete, reliable, fit for any particular purpose or merchantable and does not accept liability for any act (or decision not to act) resulting from use of this document and related data. To the maximum extent permissible all warranties and other assurances by Nomura group are hereby excluded and Nomura Group shall have no liability for the use, misuse, or distribution of this information.

Opinions or estimates expressed are current opinions as of the original publication date appearing on this material and the information, including the opinions and estimates contained herein, are subject to change without notice. Nomura Group is under no duty to update this document. Any comments or statements made herein are those of the author(s) and may differ from views held by other parties within Nomura Group. Clients should consider whether any advice or recommendation in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. Nomura Group does not provide tax advice

Nomura Group, and/or its officers, directors and employees, may, to the extent permitted by applicable law and/or regulation, deal as principal, agent, or otherwise, or have long or short positions in, or buy or sell, the securities, commodities or instruments, or options or other derivative instruments based thereon, of issuers or securities mentioned herein. Nomura Group companies may also act as market maker or liquidity provider (as defined within Financial Services Authority ('FSA') rules in the UK) in the financial instruments of the issuer. Where the activity of market maker is carried out in accordance with the definition given to it by specific laws and regulations of the US or other jurisdictions, this will be separately disclosed within the specific issuer disclosures.

This document may contain information obtained from third parties, including ratings from credit ratings agencies such as Standard & Poor's. Reproduction and distribution of third party content in any form is prohibited except with the prior written permission of the related third party. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings. Credit ratings are statements of opinions and are not statements of fact or recommendations to purchase hold or sell securities. They do not address the suitability of securities or the suitability of securities for investment purposes, and should not be relied on as investment advice.

Any MSCI sourced information in this document is the exclusive property of MSCI Inc. ('MSCI'). Without prior written permission of MSCI, this information and any other MSCI intellectual property may not be reproduced, re-disseminated or used to create any financial products, including any indices. This information is provided on an "as is" basis. The user assumes the entire risk of any use made of this information. MSCI, its affiliates and any third party involved in, or related to, computing or compiling the information hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to any of this information. Without limiting any of the foregoing, in no event shall MSCI, any of its affiliates or any third party involved in, or related to, computing or compiling the information have any liability for any damages of any kind. MSCI and the MSCI indexes are services marks of MSCI and its affiliates. Investors should consider this document as only a single factor in making their investment decision and, as such, the report should not be viewed as identifying or suggesting all risks, direct or indirect, that may be associated with any investment decision. Nomura Group produces a number of different types of research product including, among others, fundamental analysis, quantitative analysis and short term trading ideas; recommendations contained in one type of research product may differ from recommendations contained in other types of research product, whether as a result of differing time horizons, methodologies or otherwise. Nomura Group publishes research product in a number of different ways including the posting of product on Nomura Group portals and/or distribution directly to clients. Different groups of clients may receive different products and services from the research department depending on their individual requirements. Clients outside of the US may access the Nomura Research Trading Ideas platform (Retina) at http://go.nomuranow.com/equities/tradingideas.

Figures presented herein may refer to past performance or simulations based on past performance which are not reliable indicators of future performance. Where the information contains an indication of future performance, such forecasts may not be a reliable indicator of future performance. Moreover, simulations are based on models and simplifying assumptions which may oversimplify and not reflect the future distribution of returns. Certain securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of, or income derived from, the investment.

The securities described herein may not have been registered under the US Securities Act of 1933 (the '1933 Act'), and, in such case, may not be offered or sold in the US or to US persons unless they have been registered under the 1933 Act, or except in compliance with an exemption from the registration requirements of the 1933 Act. Unless governing law permits otherwise, any transaction should be executed via a Nomura entity in your home jurisdiction.

This document has been approved for distribution in the UK and European Economic Area as investment research by NIplc, which is authorized and regulated by the FSA and is a member of the London Stock Exchange. It does not constitute a personal recommendation, as defined by the FSA, or take into account the particular investment objectives, financial situations, or needs of individual investors. It is intended only for investors who are 'eligible counterparties' or 'professional clients' as defined by the FSA, and may not, therefore, be redistributed to retail clients as defined by the FSA. This document has been approved by NIHK, which is regulated by the Hong Kong Securities and Futures Commission, for distribution in Hong Kong by NIHK. This document has been approved for distribution in Australia by NAL, which is authorized and regulated in Australia by the ASIC. This document has also been approved for distribution in Malaysia by NSM. In Singapore, this document has been distributed by NSL. NSL accepts legal responsibility for the content of this document, where it concerns securities, futures and foreign exchange, issued by their foreign affiliates in respect of recipients who are not accredited, expert or institutional investors as defined by the Securities and Futures Act (Chapter 289). Recipients of this document in Singapore should contact NSL in respect of matters arising from, or in connection with, this document.

Unless prohibited by the provisions of Regulation S of the 1933 Act, this material is distributed in the US, by NSI, a US-registered broker-dealer, which accepts responsibility for its contents in accordance with the provisions of Rule 15a-6, under the US Securities Exchange Act of 1934. This document has not been approved for distribution in the Kingdom of Saudi Arabia ('Saudi Arabia') or to clients other than 'professional clients' in the United Arab Emirates ('UAE') by Nomura Saudi Arabia, NIplc or any other member of Nomura Group, as the case may be. Neither this document nor any copy thereof may be taken or transmitted or distributed, directly or indirectly, by any person other than those authorised to do so into Saudi Arabia or in the UAE or to any person located in Saudi Arabia or to clients other than 'professional clients' in the UAE. By accepting to receive this document, you represent that you are not located in Saudi Arabia or that you are a 'professional client' in the UAE and agree to comply with these restrictions. Any failure to comply with these restrictions may constitute a

violation of the laws of the UAE or Saudi Arabia. NO PART OF THIS MATERIAL MAY BE (I) COPIED, PHOTOCOPIED, OR DUPLICATED IN ANY FORM, BY ANY MEANS; OR (II) REDISTRIBUTED WITHOUT THE PRIOR WRITTEN CONSENT OF A MEMBER OF NOMURA GROUP. If this document has been distributed by electronic transmission, such as e-mail, then such transmission cannot be guaranteed to be secure or error-free as information could be intercepted, corrupted, lost, destroyed, arrive late or incomplete, or contain viruses. The sender therefore does not accept liability for any errors or omissions in the contents of this document, which may arise as a result of electronic transmission. If verification is required, please request a hard-copy version.

Nomura Group manages conflicts with respect to the production of research through its compliance policies and procedures (including, but not limited to, Conflicts of Interest, Chinese Wall and Confidentiality policies) as well as through the maintenance of Chinese walls and employee training.

Additional information is available upon request and disclosure information is available at the Nomura Disclosure web page: <u>http://go.nomuranow.com/research/globalresearchportal/pages/disclos</u> Copyright © 2013 Nomura International (Hong Kong) Ltd. All rights reserved.